Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Baxter
Medtronic
McKesson
McKinsey

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR OPSUMIT


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Opsumit

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02050802 ↗ Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects Completed Actelion Phase 1 2011-08-01 The study is intended to demonstrate that macitentan does not have an effect on cardiac repolarization exceeding the threshold of regulatory concern after repeated administration of daily oral doses of 10 and 30 mg to healthy male and female subjects.
NCT02126943 ↗ OPsumit USers Registry Completed Actelion 2014-04-30 Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.
NCT02476864 ↗ Comparison of the Pharmacokinetic Properties of Two Tablet Formulations of Macitentan in Healthy Adults Completed Actelion Phase 1 2015-08-01 A study conducted in healthy adults to investigate if a new macitentan tablet leads to the same fate of macitentan in the body (time of onset, time of presence, amount in the blood) as the marketed macitentan tablet.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Opsumit

Condition Name

Condition Name for Opsumit
Intervention Trials
Healthy 5
Pulmonary Arterial Hypertension 3
Healthy Subjects 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Opsumit
Intervention Trials
Hypertension 5
Pulmonary Arterial Hypertension 3
Familial Primary Pulmonary Hypertension 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Opsumit

Trials by Country

Trials by Country for Opsumit
Location Trials
United States 64
Germany 3
Japan 2
Canada 2
Belgium 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Opsumit
Location Trials
Massachusetts 3
Arizona 3
California 3
Maryland 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Opsumit

Clinical Trial Phase

Clinical Trial Phase for Opsumit
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Opsumit
Clinical Trial Phase Trials
Completed 6
Recruiting 3
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Opsumit

Sponsor Name

Sponsor Name for Opsumit
Sponsor Trials
Actelion 9
Janssen Research & Development, LLC 2
Boston University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Opsumit
Sponsor Trials
Industry 12
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
McKinsey
Johnson and Johnson
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.